RA Capital Healthcare Fund LP 4
4 · Adicet Bio, Inc. · Filed Apr 13, 2026
Research Summary
AI-generated summary of this filing
Adicet Bio (ACET) 10% Owner RA Capital Buys Shares
What Happened
RA Capital Management, L.P. (a reported 10% owner via its RA Capital Healthcare Fund) acquired a total of 223,596 Adicet Bio (ACET) shares in three open-market purchases in February 2026. The buys were: 74,577 shares at a weighted-average $7.04 ($525,022) on 2026-02-18; 74,268 shares at $7.21 ($535,472) on 2026-02-19; and 74,751 shares at $7.27 (~$543,440) on 2026-02-20 — about $1.60 million total. These were purchases (buying = generally a more informative/bullish signal than sales), not sales or option exercises.
Key Details
- Transaction dates and reported weighted-average prices:
- 2026-02-18: 74,577 shares @ $7.04 (~$525,022)
- 2026-02-19: 74,268 shares @ $7.21 (~$535,472)
- 2026-02-20: 74,751 shares @ $7.27 (~$543,440)
- Total shares bought: 223,596; total reported value: ~$1,603,934.
- Shares held after transaction: not specified in the provided excerpt.
- Footnotes of note:
- Reported prices are weighted averages from multiple trades; component prices reported in the filing range roughly $6.89 to $7.58.
- RA Capital Management is the adviser to RA Capital Healthcare Fund; the Fund directly holds the shares and the adviser/disclosers disclaim beneficial ownership except for pecuniary interest.
- Filing timeliness: The Form 4 was filed 2026-04-13 for February trades (transactionTimeliness = 'L'), indicating a late filing. Late filings reduce timely public transparency and can carry regulatory attention.
Context
- This activity is institutional (a 10% owner via a fund), not an individual executive or director trade; institutional purchases are commonly portfolio/investment decisions rather than personal insider signals.
- No options, awards, gifts, or tax-withholding events are reported here — only open-market purchases.
Insider Transaction Report
Form 4
Adicet Bio, Inc.ACET
RA CAPITAL MANAGEMENT, L.P.
10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F3]2026-02-18$7.04/sh+74,577$525,022→ 1,033,605 total(indirect: See footnotes) - Purchase
Common Stock
[F4][F2][F3]2026-02-19$7.21/sh+74,268$535,472→ 1,107,873 total(indirect: See footnotes) - Purchase
Common Stock
[F5][F2][F3]2026-02-20$7.27/sh+74,751$543,440→ 1,182,624 total(indirect: See footnotes)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.89 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.89 to $7.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.05 to $7.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.